Cantor Fitzgerald Keeps Overweight on BioMarin and MannKind
Cantor Fitzgerald reiterated Overweight on BioMarin with an $86 target and on MannKind with an $8 target, according to TradingView citing Benzinga data.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Cantor Fitzgerald analysts reiterated their Overweight rating on BioMarin Pharmaceutical shares with an $86 price target. The target implies a 57.3% gain from the October 19 close of $54.67.
For MannKind, the analysts kept the same Overweight rating with an $8 price target. The target implies a 158.9% gain from the October 19 close of $3.09. The note points to the company's product pipeline and an expected revenue ramp in the coming quarters.
The report was published by TradingView, with price target data provided by Benzinga.
why it matters
Broker rating reiterations are routine events and usually move individual stocks only briefly. For smaller-cap names such as MannKind, a large stated upside draws investor attention, but decisions in such cases should rest on each investor's own analysis.
tags
instruments
sources
- Cantor Fitzgerald reiterates Overweight rating on BioMarin Pharmaceutical, $86 price target — TradingView, 20 October 2026 at 11:12 UTC
- Cantor Fitzgerald reiterates Overweight rating on MannKind, $8 price target — TradingView, 20 October 2026 at 11:10 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗